stocksfeed.ai
← Back to news feed

SMMT overview

SMMT
Summit Therapeutics Inc.
10.50
USD
-2.07 (-16.46%)since Nov 16, 2026

News about SMMT

5 stories shown

SMMTregulation

Summit Therapeutics' stock tumbled after the FDA recommended a new trial for its lung-cancer drug following an extensive regulatory disclosure.

MarketWatch
View original
SMMTregulation

The FDA declined to approve Summit Therapeutics' lung-cancer drug because it needs to prove it can help people live longer.

MarketWatch
View original

U.S. stock futures traded mixed on Monday while Treasury Secretary Scott Bessent pressed Nvidia over export compliance and several individual stocks made notable premarket moves.

Benzinga
View original
SMMTregulation

The FDA declined approval for Summit Therapeutics' ivonescimab combined with chemotherapy as a treatment for advanced lung cancer due to insufficient evidence of longer survival.

Seeking Alpha
View original